Skip to main content
Midas Edge

Coherus Oncology, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

CHRS$0.64-21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · ​ ​ ​ · Shares · ​ ​ ​ · ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Loss · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balances at December 31, 2025121,154,925​$12​$1,444,166​$(195)​$(1,382,969)​$61,014
Net loss—​—​—​—​(38,327)​(38,327)
Issuance of common stock upon exercise of stock options​56,705​—​57​—​—​57
Issuance of common stock upon vesting of restricted stock units ("RSUs")​188,057​—​—​—​—​—
Taxes paid related to net share settlement of RSUs​(72,078)​​—​​(112)​​—​​—​​(112)
Issuance of common stock under Public Offering, net of issuance costs​32,890,000​​3​​53,647​​—​​—​​53,650
Stock-based compensation expense​—​—​2,414​—​—​2,414
Other comprehensive loss, net of tax​—​​—​​—​​(73)​​—​​(73)
Balances at March 31, 2026154,217,609​​15​​1,500,172​​(268)​​(1,421,296)​​78,623
Net loss—​—​—​—​(20,631)​(20,631)
Issuance of common stock upon exercise of stock options42,457​—​58​—​—​58
Issuance of common stock under the employee stock purchase plan ("ESPP")210,297​—​202​—​—​202
Stock-based compensation expense—​—​2,599​—​—​2,599
Other comprehensive loss, net of tax​—​​—​​—​​(13)​​—​​(13)
Balances at June 30, 2026154,470,363​$15​$1,503,031​$(281)​$(1,441,927)​$60,838
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · ​ ​ ​ · Shares · ​ ​ ​ · ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Loss · ​ ​ ​ · Deficit · ​ ​ ​ · Equity (Deficit)
Balances at December 31, 2024115,614,548​$12​$1,419,266​$(275)​$(1,550,993)​$(131,990)
Net loss—​—​—​—​(56,569)​(56,569)
Issuance of common stock upon vesting of RSUs474,410​—​—​—​—​—
Taxes paid related to net share settlement of RSUs​(181,742)​​—​​(264)​​—​​—​​(264)
Stock-based compensation expense—​—​5,353​—​—​5,353
Balances at March 31, 2025115,907,216​​12​​1,424,355​​(275)​​(1,607,562)​​(183,470)
Net income—​—​—​—​297,767​297,767
Issuance of common stock upon vesting of RSUs​44,556​—​—​—​—​—
Taxes paid related to net share settlement of RSUs​(16,519)​​—​​(16)​​—​​—​​(16)
Issuance of common stock under the ESPP287,473​—​188​—​—​188
Stock-based compensation expense—​—​5,358​—​—​5,358
Balances at June 30, 2025116,222,726​$12​$1,429,885​$(275)​$(1,309,795)​$119,827
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.